Pediatric Down Syndrome Post-Approval Study
Inspire Medical Systems, Inc. · NCT06851338
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 13–18 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 60
- US sites recruiting
- 1
- Study start
- February 2025
- Record last updated
- February 28, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this Post Approval research study is to assess ongoing safety and effectiveness of the Inspire therapy in adolescents and young adults (age 13-18) with Down syndrome and severe sleep apnea. The objective of the study is to provide an ongoing safety and effectiveness assessment of the Inspire UAS System in the Pediatric Down syndrome population.
Being studied: Hypoglossal Nerve Stimulation
Conditions: Pediatric Obstructive Sleep Apnea; Down Syndrome (DS)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Patient has been diagnosed with Down syndrome;
- Patient is 13-18 years of age;
- Patient has been diagnosed with severe obstructive sleep apnea, with an AHI of ≥ 10 and ≤ 50 based on a recent (within 6 months of enrollment) qualified in-lab sleep study (PSG);
- Patient has documented failure of, or intolerance to, positive airway pressure therapies (such as CPAP or BiPAP) despite attempts to improve compliance;
- Patient is contraindicated for, or not effectively treated by, adenotonsillectomy;
- Treatment of patient's OSA has followed standard of care in considering all other alternative/adjunctive therapies;
- Patient, and their parents/guardians, is willing to have stimulation hardware permanently implanted, and be willing to participate in follow-up visits, postoperative in-lab sleep studies (PSGs), and questionnaire completion.
Exclusion Criteria
- Patient's recent PSG (within 6 months of enrollment) reports central + mixed apneas > 25% of the total apnea-hypopnea index (AHI);
- Patient has any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate;
- Patient has any condition or procedure that has compromised neurological control of the upper airway;
- Patient, or their parent/guardian, is unable or does not have the necessary assistance to operate the patient remote;
- Patient is pregnant or plans to become pregnant;
- Patient has an implantable device that may be susceptible to unintended interaction with the Inspire system;
- Patient will require magnetic resonance imaging (MRI) other than what is specified in the MR conditional labeling;
- Patient has a terminal illness with life expectancy of less than 12 months;
- Any other reason the investigator deems the patient is unfit for participation in the study.
Recruiting US locations
Baylor College of Medicine/ Texas Children's Hospital
Houston, TX 77030
Site contact: Sadaf Batla · sxbatla@texaschildrens.org
Study contacts (from the official record)
- Angela Chapin, Sr. Clinical Study Manager · 763.392.7222 · angelachapin@inspiresleep.com
- Gwen Gimmestad, VP Clinical · 763.392.9966 · gwengimmestad@inspiresleep.com
Similar studies in Texas
All sleep studies in Texas →- RecruitingHealthy volunteers
Safety and Effectiveness of Slow Wave Device for the Treatment of Obstructive Sleep Apnea
Slow Wave, Inc.
- Location
- Austin, TX
- Eligibility basics
- Ages 18+
- Recruiting
Janus II Feasibility
Zoll Medical Corporation
- Location
- Houston, TX + 3 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Axsome Therapeutics, Inc.
- Location
- Austin, TX + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
Incannex Healthcare Ltd
- Location
- Dallas, TX + 11 other US sites
- Eligibility basics
- Ages 18–65